Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C127817
http://purl.obolibrary.org/obo/NCIT_C127817
|
|---|---|
| Preferred Name | Tapotoclax |
| Definitions |
An inhibitor of induced myeloid leukemia cell differentiation protein MCL-1 (myeloid cell leukemia-1), with potential pro-apoptotic and antineoplastic activities. Upon administration, tapotoclax binds to and inhibits the activity of MCL-1. This disrupts the formation of MCL-1/Bcl-2-like protein 11 (BCL2L11; BIM) complexes and induces apoptosis in tumor cells. MCL-1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An inhibitor of induced myeloid leukemia cell differentiation protein MCL-1 (myeloid cell leukemia-1), with potential pro-apoptotic and antineoplastic activities. Upon administration, tapotoclax binds to and inhibits the activity of MCL-1. This disrupts the formation of MCL-1/Bcl-2-like protein 11 (BCL2L11; BIM) complexes and induces apoptosis in tumor cells. MCL-1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival. |
|---|---|
| prefLabel | Tapotoclax
|
| label | Tapotoclax
|
| NCI_META_CUI | CL507931
|
| PDQ_Closed_Trial_Search_ID | 781850
|
| code | C127817
|
| Has_Target | |
| prefixIRI | NCIT:C127817
|
| in_subset |
See more
See less
|
| Display_Name | Tapotoclax
|
| Preferred_Name | Tapotoclax
|
| FDA_UNII_Code | 97W7N9T08G
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To |
MCL-1 Inhibitor AMG 176
Tapotoclax
|
| CAS_Registry | 1883727-34-1
|
| NCI_Drug_Dictionary_ID | 781850
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 781850
|
| Semantic_Type | Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |